EXACT Sciences Co. (EXAS) Insider Graham Peter Lidgard Sells 58,000 Shares

Share on StockTwits

EXACT Sciences Co. (NASDAQ:EXAS) insider Graham Peter Lidgard sold 58,000 shares of the business’s stock in a transaction dated Monday, October 8th. The stock was sold at an average price of $69.36, for a total transaction of $4,022,880.00. Following the sale, the insider now directly owns 204,684 shares in the company, valued at approximately $14,196,882.24. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Shares of EXAS opened at $67.22 on Friday. The company has a quick ratio of 15.37, a current ratio of 15.79 and a debt-to-equity ratio of 0.87. The stock has a market cap of $9.69 billion, a price-to-earnings ratio of -69.26 and a beta of 0.98. EXACT Sciences Co. has a 12-month low of $37.36 and a 12-month high of $81.22.

EXACT Sciences (NASDAQ:EXAS) last announced its earnings results on Wednesday, August 1st. The medical research company reported ($0.30) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.33) by $0.03. The company had revenue of $102.89 million during the quarter, compared to analysts’ expectations of $104.40 million. EXACT Sciences had a negative net margin of 35.24% and a negative return on equity of 20.10%. The firm’s quarterly revenue was up 78.5% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.27) earnings per share. As a group, research analysts anticipate that EXACT Sciences Co. will post -1.41 earnings per share for the current year.

A number of analysts recently commented on the stock. BidaskClub raised shares of EXACT Sciences from a “hold” rating to a “buy” rating in a report on Wednesday, September 26th. Benchmark reissued a “hold” rating on shares of EXACT Sciences in a report on Wednesday, September 5th. Cowen boosted their price objective on shares of EXACT Sciences from $65.00 to $100.00 and gave the stock an “outperform” rating in a report on Wednesday, September 5th. Robert W. Baird boosted their price objective on shares of EXACT Sciences from $74.00 to $85.00 and gave the stock an “outperform” rating in a report on Tuesday, September 11th. Finally, Canaccord Genuity boosted their price objective on shares of EXACT Sciences from $72.00 to $87.00 and gave the stock a “buy” rating in a report on Wednesday, September 12th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the company’s stock. EXACT Sciences has a consensus rating of “Buy” and a consensus price target of $83.25.

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Zevenbergen Capital Investments LLC raised its position in EXACT Sciences by 1.8% during the second quarter. Zevenbergen Capital Investments LLC now owns 2,070,170 shares of the medical research company’s stock worth $123,775,000 after acquiring an additional 35,725 shares during the last quarter. Artisan Partners Limited Partnership raised its position in EXACT Sciences by 25.8% during the second quarter. Artisan Partners Limited Partnership now owns 1,879,525 shares of the medical research company’s stock worth $112,377,000 after acquiring an additional 385,766 shares during the last quarter. Frontier Capital Management Co. LLC raised its position in EXACT Sciences by 2.7% during the second quarter. Frontier Capital Management Co. LLC now owns 1,151,667 shares of the medical research company’s stock worth $68,858,000 after acquiring an additional 30,376 shares during the last quarter. CIBC Private Wealth Group LLC raised its position in EXACT Sciences by 76.9% during the second quarter. CIBC Private Wealth Group LLC now owns 1,107,136 shares of the medical research company’s stock worth $66,196,000 after acquiring an additional 481,230 shares during the last quarter. Finally, Jennison Associates LLC raised its position in EXACT Sciences by 0.4% during the second quarter. Jennison Associates LLC now owns 966,260 shares of the medical research company’s stock worth $57,773,000 after acquiring an additional 4,096 shares during the last quarter. Institutional investors own 86.39% of the company’s stock.

About EXACT Sciences

Exact Sciences Corporation, a molecular diagnostics company, focuses on developing products for the early detection and prevention of various cancers in the United States. The company offers Cologuard, a non-invasive stool-based DNA screening test for the early detection of colorectal cancer and pre-cancer.

Read More: What is the Ex-Dividend Date in Investing?

Insider Buying and Selling by Quarter for EXACT Sciences (NASDAQ:EXAS)

Receive News & Ratings for EXACT Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EXACT Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply